Journal Mobile Options
Table of Contents
Vol. 11, No. 3, 2000
Issue release date: May–June 2000
Dement Geriatr Cogn Disord 2000;11:139–146
(DOI:10.1159/000017227)

Features of Regional Cerebral Glucose Metabolism Abnormality in Corticobasal Degeneration

Hirono N. · Ishii K. · Sasaki M. · Kitagaki H. · Hashimoto M. · Imamura T. · Tanimukai S. · Hanihara T. · Kazui H. · Mori E.
Divisions of aClinical Neurosciences and bNeuroimaging Research, Hyogo Institute for Aging Brain and Cognitive Disorders, Himeji, Japan

Individual Users: Register with Karger Login Information

Please create your User ID & Password





Contact Information











I have read the Karger Terms and Conditions and agree.

To view the fulltext, please log in

To view the pdf, please log in

Abstract

We studied regional cerebral glucose metabolism in 15 patients with a clinical diagnosis of corticobasal degeneration (CBD), 15 patients with probable Alzheimer’s disease (AD), and 15 healthy controls for 19 brain regions. Asymmetry in regional glucose metabolism was found in the central and frontal cortices in patients with CBD as compared with either the normal controls or the patients with AD. Regional glucose metabolism in CBD patients was significantly lower in the paracentral and superior parietal areas and thalamus than in patients with AD. Relative glucose metabolism in patients with CBD was significantly higher in the posterior cingulate, medial temporal and basal frontal areas, and significantly lower in the paracentral and superior parietal areas than in those with AD. These features of regional glucose metabolic abnormality in CBD may correspond to neurological and cognitive disturbances peculiar to CBD.

Copyright © 2000 S. Karger AG, Basel



Copyright / Drug Dosage

Copyright: All rights reserved. No part of this publication may be translated into other languages, reproduced or utilized in any form or by any means, electronic or mechanical, including photocopying, recording, microcopying, or by any information storage and retrieval system, without permission in writing from the publisher or, in the case of photocopying, direct payment of a specified fee to the Copyright Clearance Center.
Drug Dosage: The authors and the publisher have exerted every effort to ensure that drug selection and dosage set forth in this text are in accord with current recommendations and practice at the time of publication. However, in view of ongoing research, changes in goverment regulations, and the constant flow of information relating to drug therapy and drug reactions, the reader is urged to check the package insert for each drug for any changes in indications and dosage and for added warnings and precautions. This is particularly important when the recommended agent is a new and/or infrequently employed drug.
Disclaimer: The statements, opinions and data contained in this publication are solely those of the individual authors and contributors and not of the publishers and the editor(s). The appearance of advertisements or/and product references in the publication is not a warranty, endorsement, or approval of the products or services advertised or of their effectiveness, quality or safety. The publisher and the editor(s) disclaim responsibility for any injury to persons or property resulting from any ideas, methods, instructions or products referred to in the content or advertisements.

References

  1. Rebeiz JJ, Kolodny EH, Richardson EP: Corticodentatonigral degeneration with neuronal achromasia. Arch Neurol 1968;18:20–33.
  2. Riley DE, Lang AE, Lewis A, Resch L, Ashby P, Hornykiewicz O, Black S: Cortical-basal ganglionic degeneration. Arch Neurol 1990;40:1203–1212.
  3. Lang AE, Riley DE, Bergeron C: Cortical-basal ganglionic degeneration; in Calne DB (ed): Neurodegenerative Disease. Philadelphia, Saunders, 1994, pp 877–894.
  4. Gibb WRG, Luthert PJ, Marsden CD: Corticobasal degeneration. Brain 1989;112:1171–1192.

    External Resources

  5. Rinne JO, Lee MS, Thompson PD, Marsden CD: Corticobasal degeneration: A clinical study of 36 cases. Brain 1994;117:1183–1196.

    External Resources

  6. Litvan I, Agid Y, Goetz C, Jankovic J, Wenning GK, Brandel JP, Lai EC, Verny M, Ray-Chaudhuri K, McKee A, Jellinger K, Pearce RKB, Bartko JJ: Accurary of the clinical diagnosis of corticobasal degeneration. Neurology 1997;48:119–125.
  7. Lippa CF, Cohen R, Smith TW, Drachman DA: Primary progressive aphasia with focal neuronal achromasia. Neurology 1991;41:882–886.
  8. Pillon B, Blin J, Vidailhet M, Deweer B, Sirigu A, Dubois B, Agid Y: The neuropsychological pattern of corticobasal degeneration: Comparison with progressive supranuclear palsy and Alzheimer’s disease. Neurology 1995;45:1477–1483.
  9. Markus HS, Lees AJ, Lennox G, Marsden CD, Costa DC: Patterns of regional cerebral blood flow in corticobasal degeneration studied using HMPAO SPECT: Comparison with Parkinson’s disease and normal controls. Mov Disord 1995;10:179–187.
  10. Eidelberg D, Dhawan V, Moeller JR, Sidtis JJ, Ginos JZ, Strother SC, Cederbaum J, Greene P, Fahn S, Powers JM, Rottenberg DA: The metabolic landscape of cortico-basal ganglionic degeneration: Regional asymmetries studied with positron emission tomography. J Neurol Neurosurg Psychiatry 1991;54:856–862.
  11. Sawle GV, Brooks DJ, Marsden CD, Frackowiak RS: Corticobasal degeneration. A unique pattern of regional cortical oxygen hypometabolism and striatal fluorodopa uptake demonstrated by positron emission tomography. Brain 1991;114:541–556.

    External Resources

  12. Blin J, Vidailhet MJ, Pillon B, Dubois B, Feve JR, Agid Y: Corticobasal degeneration: Decreased and asymmetrical glucose consumption as studied with PET. Mov Disord 1992;7:348–354.
  13. Nagasawa H, Tanji H, Nomura H, Saito H, Itoyama Y, Kimura I, Tuji S, Fujiwara T, Iwata R, Itoh M, Ido T: PET study of cerebral glucose metabolism and fluorodopa uptake in patients with corticobasal degeneration. J Neurol Sci 1996;139:210–217.

    External Resources

  14. Nagahama Y, Fukuyama H, Turjanski N, Kennedy A, Yamauchi H, Ouchi Y, Kimura J: Cerebral glucose metabolism in corticobasal degeneration: Comparison with progressive supranuclear palsy and normal controls. Mov Disord 1997;12:691–696.
  15. Mori E, Mitani Y, Yamadori A: Usefulness of Japanese version of the Mini-Mental State test in neurological patients. Jpn J Neuropsychiatry 1985;1:82–90.
  16. McKhann G, Drachman D, Folstein M, Katzman R, Price D, Stadlan E: Clinical diagnosis of Alzheimer’s disease: Report of the NINCDS-ADRDA Work Group under the auspices of Department of Health and Human Services Task Force on Alzheimer’s Disease. Neurology 1984;34:939–944.
  17. Hirono N, Mori E, Ishii K, Ikejiri Y, Imamura T, Shimomura T, Ikeda M, Yamashita H, Takatsuki Y, Sasaki M: Regional hypometaolism related to language disturbance in Alzheimer’s disease. Dement Geriatr Cogn Disord 1998;9:68–73.
  18. Hirono N, Mori E, Yasuda M, Ishii K, Ikejiri Y, Imamura T, Shimomura T, Hashimoto M, Yamashita H, Sasaki M: Lack of association of apolipoprotein E e4 allele dose with cerebral glucose metabolism in Alzheimer’s disease. Alzheimer Dis Assoc Dis 1998;12:362–367.
  19. Ishii K, Sasaki M, Kitagaki H, Yamaji S, Sakamoto S, Matsuda K, Mori E: Reduction of cerebellar glucose metabolism in advanced Alzheimer’s disease. J Nucl Med 1997;38:925–928.
  20. Hirono N, Mori E, Ishii K, Ikejiri Y, Imamura T, Shimomura T, Hashimoto M, Yamashita H, Sasaki M: Frontal lobe hypometabolism and depression in Alzheimer’s disease. Neurology 1998;50:380–383.
  21. Ishii K, Imamura T, Sasaki M, Yamaji S, Sakamoto S, Kitagaki H, Hashimoto M, Hirono N, Shimomura T, Mori E: Regional cerebral glucose metabolism in dementia with Lewy bodies and Alzheimer’s disease. Neurology 1998;51:125–130.
  22. Hirono N, Mori E, Ishii K, Kitagaki H, Sasaki M, Ikejiri Y, Imamura T, Shimomura T, Ikeda M, Yamashita H: Alteration of regional cerebral glucose utilization with delusions in Alzheimer’s disease. J Neuropsychiatry Clin Neurosci 1998;10:433–439.
  23. Hirono N, Mori E, Ishii K, Ikejiri Y, Imamura T, Shimomura T, Hashimoto M, Yamashita H, Sasaki M: Hypofunction in posterior cingulate gyrus correlates with disorientation for time and place in Alzheimer’s disease. J Neurol Neurosurg Psychiatry 1998;64:552–554.
  24. Hirono N, Mori E, Ishii K, Imamura T, Shimomura T, Tanimukai S, Kazui H, Hashimoto M, Yamashita H, Sasaki M: Regional metabolism: Association with dyscalculia in Alzheimer’s disease. J Neurol Neurosurg Psychiatry 1998;65:913–916.
  25. Rosen WG, Mohs RC, Davis KL: A new rating scale for Alzheimer’s disease. Am J Psychiatry 1984;141:1356–1364.
  26. Ishii K, Sasaki M, Sakamoto S, Kitagaki H, Yamaji S, Maeda K: Regional difference of cerebral blood flow and oxidative metabolism in human cortex. J Nucl Med 1996;37:1086–1088.
  27. Iida H, Miura S, Kanno I, Murakami M, Yamamoto S, Amano M: Design of evaluation of Headtome IV: A whole body positron emission tomograph. IEEE Trans Nucl Sci 1989;NS-37:1006–1010.
  28. Phelps ME, Huang SC, Hoffman EJ, Selin C, Sokoloff L, Kuhl DE: Tomographic measurement of local cerebral glucose metabolic rate in humans with (F-18)2-fluoro-2-deoxy-D-glucose: validation of method. Ann Neurol 1979;6:371–388.

    External Resources

  29. Talairach J, Tournoux P: Co-Planar Stereotaxic Atlas of the Human Brain. Stuttgart, Thieme, 1988.
  30. Bergeron C, Pollanen MS, Weyer L, Lang AE: Cortical degeneration in progressive supranuclear palsy. A comparison with cortical-basal ganglionic degeneration. J Neuropathol Exp Neurol 1997;56:726–734.
  31. Lang AE, Bergeron C, Pollanen MS, Ashby P: Parietal Pick’s disease mimicking cortical-basal ganglionic degeneration. Neurology 1994;44:1436–1440.
  32. Cummings JL, Benson DF: Dementia: A Clinical Approach, ed 2. Boston, Butterworth-Heinemann, 1992.
  33. Ishii K, Kitagaki H, Kono M, Mori E: Decreased medial temporal oxygen metabolism in Alzheimer’s disease shown by positron emission tomography. J Nucl Med 1996;37:1159–1165.
  34. Ishii K, Sasaki M, Yamaji S, Sakamoto S, Kitagaki H, Mori E: Demonstration of decreased posterior cingulate perfusion in mild Alzheimer’s disease by means of H215O positron emission tomography. Eur J Nucl Med 1997;24:670–673.
  35. Minoshima S, Giordani B, Berent S, Frey KA, Foster NL, Kuhl DE: Metabolic reduction in the posterior cingulate cortex in very early Alzheimer’s disease. Ann Neurol 1997;42:85–94.
  36. Squire LR: Memory and Brain. Oxford, Oxford University Press, 1987.
  37. Benton A: Constructional apraxia; in Boller F, Grafman J, Goodglass H, Damasio AR (eds): Handbook of Neuropsychology. Amsterdam, Elsevier, 1989, vol 2, pp 387–394.
  38. De Renti E: Apraxia; in Boller F, Grafman J, Goodglass H, Damasio AR (eds): Handbook of Neuropsychology. Amsterdam, Elsevier, 1989, vol 2, pp 245–263.


Pay-per-View Options
Direct payment This item at the regular price: USD 38.00
Payment from account With a Karger Pay-per-View account (down payment USD 150) you profit from a special rate for this and other single items.
This item at the discounted price: USD 26.50